Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO | Taiwan News taiwannews.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from taiwannews.com.tw Daily Mail and Mail on Sunday newspapers.
BEIJING and SHANGHAI and CHICAGO, June 2, 2024 /PRNewswire/ Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets,
/PRNewswire/ Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, presented updated data of a KRAS G12C inhibitor.
Glecirasib has demonstrated activity in a phase 2 trial of patients with KRAS G12C-mutated, advanced NSCLC. Glecirasib has demonstrated activity in a phase 2 trial of patients with KRAS G12C-mutated, advanced NSCLC.
/PRNewswire/ Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically.